GlassScriptPhysician profile
Broderick C Bello
NPI 1689668535
$1,940.26
in general payments reported to CMS, 2019-2025
25 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $212 · 2021: $293 · 2022: $297 · 2023: $608 · 2024: $156 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $303.82 | 2020-2024 | Breztri, Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $238.24 | 2020-2021 | |
| Glaxosmithkline, LLC. | $175.86 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk As | $82.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.96 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $78.12 | 2019-2023 | Mounjaro |
| Amgen INC. | $66.97 | 2019-2025 | Repatha |
| Abbott Laboratories | $50.19 | 2022 | |
| Amarin Pharma, INC. | $50.00 | 2019 | |
| Abbvie INC. | $47.34 | 2023-2024 | Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.46 | 2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $28.47 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $22.83 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.39 | 2025 | Camzyos |
| Sunovion Pharmaceuticals INC. | $21.30 | 2022 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Exact Sciences Corporation | $18.02 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2021 | |
| Sumitomo Pharma America, INC. | $15.92 | 2023 | Gemtesa |
| Biogen, INC. | $15.86 | 2021 | |
| Lundbeck LLC | $14.04 | 2024 | Rexulti |
| Allergan, INC. | $13.81 | 2020 | |
| Nevro Corp. | $13.67 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Broderick Bello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.